Figure 2. Exploitation of a mitochondrial UPR for cancer therapy.

Mitochondrial dysfunction associated with proteotoxic stress results in the upregulation of stress response transcription factors, CHOP and C/EBPβ, which in turn repress NFκB activity, sensitizing tumor cells to apoptosis-inducing agents.